Lista de obras -

A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population

artículo científico publicado en 2017

A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth

artículo científico publicado en 2007

AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma

artículo científico publicado en 2006

Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice

artículo científico publicado en 2007

An integrated genomic analysis of human glioblastoma multiforme

artículo científico publicado en 2008

Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program.

artículo científico publicado en 2011

Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.

artículo científico publicado en 2011

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.

artículo científico publicado en 2005

ET-28COMBINATION THERAPY WITH MET TYROSINE KINASE INHIBITOR EMD1214063 AND BEVACIZUMAB.

artículo científico publicado en 2014

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.

artículo científico publicado en 2011

Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis

artículo científico publicado en 2016

Exercise interest and preferences among patients diagnosed with primary brain cancer

artículo científico publicado en 2006

Exomic sequencing of four rare central nervous system tumor types

artículo científico publicado en 2013

Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.

artículo científico publicado en 2016

Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program

artículo científico publicado en 2015

Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program

artículo científico publicado en 2014

Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.

artículo científico publicado en 2011

Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program

artículo científico publicado en 2013

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling

artículo científico publicado en 2011

Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.

artículo científico publicado en 2010

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program

artículo científico publicado en 2014

Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program

artículo científico publicado en 2011

Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.

artículo científico publicado en 2011

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program

artículo científico publicado en 2008

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

artículo científico publicado en 2013

Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program

artículo científico publicado en 2013

Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program

artículo científico publicado en 2009

Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program

scientific article published on February 2010

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program

artículo científico publicado en 2013

Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.

artículo científico publicado en 2010

Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program

artículo científico publicado en 2008

Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.

artículo científico publicado en 2010

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.

artículo científico publicado en 2014

Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.

artículo científico publicado en 2013

Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.

artículo científico publicado en 2016

Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.

artículo científico publicado en 2012

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program

artículo científico publicado en 2013

Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program

artículo científico publicado en 2014

Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.

scientific article published on December 2009

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.

artículo científico publicado en 2008

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

artículo científico publicado en 2011

Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program

artículo científico publicado en 2010

Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program

artículo científico publicado en 2014

Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.

artículo científico publicado en 2012

Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.

artículo científico publicado en 2011

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.

artículo científico publicado en 2008

Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program.

scientific article published on September 2009

Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.

artículo científico publicado en 2011

Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.

artículo científico publicado en 2016

Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.

artículo científico publicado en 2010

Initial testing of aplidin by the pediatric pre-clinical testing program.

artículo científico publicado en 2009

Initial testing of cisplatin by the pediatric preclinical testing program

artículo científico publicado en 2008

Initial testing of dasatinib by the pediatric preclinical testing program

artículo científico publicado en 2008

Initial testing of lenalidomide by the pediatric preclinical testing program

artículo científico publicado en 2011

Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program

artículo científico publicado en 2011

Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program

artículo científico publicado en 2012

Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program

artículo científico publicado en 2008

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

artículo científico publicado en 2010

Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.

artículo científico publicado en 2010

Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.

scientific article published on 19 October 2011

Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program

artículo científico publicado en 2010

Initial testing of topotecan by the pediatric preclinical testing program.

artículo científico publicado en 2010

Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model ⬇️

artículo científico publicado el 20 de octubre de 2012

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas

artículo científico publicado en 2014

O6-benzylguanine-mediated enhancement of chemotherapy.

artículo científico publicado en 2002

Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.

artículo científico publicado en 2015

Phosphorylation of Glutathione S-Transferase P1 (GSTP1) by Epidermal Growth Factor Receptor (EGFR) Promotes Formation of the GSTP1-c-Jun N-terminal kinase (JNK) Complex and Suppresses JNK Downstream Signaling and Apoptosis in Brain Tumor Cells

artículo científico publicado en 2015

Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft

artículo científico publicado en 2005

Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis

artículo científico publicado en 2013

Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.

artículo científico publicado en 2008

Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program

artículo científico publicado en 2010

Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.

artículo científico publicado en 2018

Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.

artículo científico publicado en 2014

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.

artículo científico publicado en 2011

Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.

artículo científico publicado en 2011

The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy

artículo científico publicado en 2024

The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion

artículo científico publicado en 2007

The genetic landscape of the childhood cancer medulloblastoma

artículo científico publicado en 2011

The pediatric preclinical testing program: description of models and early testing results.

artículo científico publicado en 2007

Using the theory of planned behavior to understand the determinants of exercise intention in patients diagnosed with primary brain cancer

artículo científico publicado en 2007

ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors

artículo científico publicado en 2005

Lista de obras de

A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population

A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth

AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma

Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice

An integrated genomic analysis of human glioblastoma multiforme

Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program.

Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.

ET-28COMBINATION THERAPY WITH MET TYROSINE KINASE INHIBITOR EMD1214063 AND BEVACIZUMAB.

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.

Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis

Exercise interest and preferences among patients diagnosed with primary brain cancer

Exomic sequencing of four rare central nervous system tumor types

Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.

Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program

Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program

Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.

Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling

Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program

Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program

Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program

Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program

Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program

Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.

Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program

Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.

Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.

Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.

Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program

Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program

Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program

Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program

Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.

Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.

Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program.

Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.

Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.

Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.

Initial testing of aplidin by the pediatric pre-clinical testing program.

Initial testing of cisplatin by the pediatric preclinical testing program

Initial testing of dasatinib by the pediatric preclinical testing program

Initial testing of lenalidomide by the pediatric preclinical testing program

Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program

Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program

Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.

Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.

Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program

Initial testing of topotecan by the pediatric preclinical testing program.

Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model ⬇️

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas

O6-benzylguanine-mediated enhancement of chemotherapy.

Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.

Phosphorylation of Glutathione S-Transferase P1 (GSTP1) by Epidermal Growth Factor Receptor (EGFR) Promotes Formation of the GSTP1-c-Jun N-terminal kinase (JNK) Complex and Suppresses JNK Downstream Signaling and Apoptosis in Brain Tumor Cells

Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft

Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis

Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.

Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program

Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.

Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.

Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.

The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy

The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion

The genetic landscape of the childhood cancer medulloblastoma

The pediatric preclinical testing program: description of models and early testing results.